Tetrahydrobiopterin: biochemistry and pathophysiology

Area of Science:

• Biochemistry and Molecular Biology
• Metabolic pathways and cofactor roles
• Enzyme kinetics and regulation

Background:

• 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) is an essential cofactor for key enzymes including aromatic amino acid hydroxylases and nitric oxide synthases (NOS).
• BH4 plays a critical role in biological processes such as neurotransmitter synthesis, cardiovascular function, immune response, and pain sensitivity.
• Dysregulation of BH4 metabolism is implicated in various pathological states, including hyperphenylalaninemia, vascular dysfunction, and neurological diseases.

Purpose of the Study:

• To elucidate the multifaceted roles of BH4 in human physiology and pathology.
• To detail the biosynthesis, salvage, and regeneration pathways of BH4.
• To explore the implications of BH4 deficiency and its therapeutic potential.

Main Methods:

• Review of existing literature on BH4 metabolism, enzyme function, and associated diseases.
• Analysis of genetic mutations affecting BH4 biosynthesis enzymes.
• Examination of the impact of oxidized BH4 on nitric oxide production and reactive oxygen species formation.

Main Results:

• BH4 is synthesized de novo from GTP or via a salvage pathway involving dihydrofolate reductase.
• GTP cyclohydrolase I is the primary regulatory point in BH4 biosynthesis, influenced by hormones and cytokines.
• Mutations in BH4 biosynthesis enzymes cause hyperphenylalaninemia; oxidized BH4 contributes to vascular dysfunction; cofactor replacement therapy is effective for BH4-responsive hyperphenylalaninemia.

Conclusions:

• BH4 is indispensable for numerous metabolic processes, and its deficiency leads to severe health consequences.
• Understanding BH4's regulatory mechanisms and pathological roles is crucial for developing targeted therapies.
• Oral BH4 supplementation offers a viable treatment strategy for specific genetic disorders like BH4-responsive hyperphenylalaninemia.